NASDAQ · SYRE
Healthcare · Biotechnology
$90.95
Up+$0.66 (+0.73%)
Updated Sep 16, 2026, 4:26 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SYRE closed at $90.95 after 20 trading sessions, down 15.65% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $90.82 | $91.07 | $88.47 | $90.95 | 858.49K |
| Sep 14, 2026 | $90.21 | $91.4025 | $89.43 | $90.80 | 1.1M |
| Sep 11, 2026 | $90.00 | $91.405 | $87.89 | $90.60 | 886.06K |
| Sep 10, 2026 | $85.56 | $88.72 | $85.26 | $88.71 | 902.46K |
| Sep 9, 2026 | $88.07 | $89.57 | $86.85 | $86.93 | 1.01M |
| Sep 8, 2026 | $85.002 | $92.10 | $85.0001 | $90.79 | 1.25M |
| Sep 4, 2026 | $86.45 | $89.18 | $84.68 | $88.98 | 803.86K |
| Sep 3, 2026 | $86.71 | $87.90 | $85.775 | $87.25 | 1.05M |
| Sep 2, 2026 | $88.05 | $90.18 | $84.00 | $87.05 | 1.36M |
| Sep 1, 2026 | $87.06 | $90.00 | $85.00 | $88.50 | 1.43M |
| Aug 31, 2026 | $89.15 | $90.965 | $86.40 | $89.33 | 1.91M |
| Aug 28, 2026 | $91.75 | $93.39 | $89.45 | $90.36 | 1.27M |
| Aug 27, 2026 | $93.61 | $94.945 | $91.25 | $93.615 | 1.17M |
| Aug 26, 2026 | $92.41 | $96.22 | $90.60 | $93.605 | 3.12M |
| Aug 25, 2026 | $109.02 | $110.15 | $106.94 | $107.36 | 923.6K |
| Aug 24, 2026 | $106.49 | $108.02 | $104.94 | $106.65 | 640.58K |
| Aug 21, 2026 | $108.85 | $110.00 | $105.71 | $106.49 | 1.01M |
| Aug 20, 2026 | $106.60 | $108.18 | $104.56 | $107.79 | 700.64K |
| Aug 19, 2026 | $110.00 | $110.175 | $104.17 | $108.92 | 1.17M |
| Aug 18, 2026 | $102.46 | $108.62 | $101.4393 | $107.82 | 949.56K |
The latest Smart Investors Daily articles mentioning SYRE.
SYRE research
Company profile and research snapshot.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Wedbush | Outperform | — |
| Sep 8, 2026 | BTIG | Buy | — |
| Aug 26, 2026 | Wedbush | Outperform | — |
| Aug 26, 2026 | BTIG | Buy | — |
| Aug 26, 2026 | Deutsche Bank | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 10, 2026
Spyre Therapeutics, Inc. (NASDAQ:SYRE) reported September 8 results from 44 patients with moderately to severely active ulcerative colitis in the open-label Part A of the Phase 2 SKYLINE trial. At week 12, the mean Robarts Histopathology Index, a measure of tissue inflammation, declined by 10 points. Clinical remission, measured by the modified Mayo Score, was […]
SeekingAlpha · Sep 9, 2026
Spyre Therapeutics, Inc. (SYRE) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 10:00 AM EDTCompany ParticipantsCameron Turtle - CEO...
Benzinga · Sep 9, 2026
Wedbush analyst David Nierengarten reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and maintains $123 price target.
Yahoo · Sep 8, 2026
SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints included clinical remission by modified Mayo Score of 20% and endoscopic improvement of 30% SPY003 was well tolerated with a safety profile consistent with the IL-23 class SKYLINE Part A has demonstrated potential best-in-class results for SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23); SKYL
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SYRE.
